Cyclic AMP-specific phosphodiesterase inhibitors

Details Cyclic AMP-specific phosphodiesterase inhibitors Cyclic AMP-specific phosphodiesterase inhibitors

2006-08-08

2006-08-08

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S374100, C514S406000

Reexamination Certificate

active

07087634

ABSTRACT:
Pyrazole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

REFERENCES:
patent: 3254093 (1966-05-01), Hans et al.
patent: 4868198 (1989-09-01), Ooms et al.
patent: 5055482 (1991-10-01), Hatton et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5434178 (1995-07-01), Talley et al.
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5958948 (1999-09-01), Bright et al.
patent: 5998428 (1999-12-01), Barnette et al.
patent: 39 34 924 (1991-04-01), None
patent: 0 151 866 (1985-08-01), None
patent: 0 285 947 (1988-10-01), None
patent: 0 936 217 (1999-08-01), None
patent: WO 94/13661 (1994-06-01), None
patent: WO 95/33727 (1995-12-01), None
patent: WO 99/58523 (1999-11-01), None
Accession No: 1984: 120955 CAPLUS, abstract of “Novel Synthesis of 1-substituted 4-hydroxypyrazoles,” Michel Albrand and Suzanne Gelin. Synthesis (1983), vol. 12, 1030-1.
Holzer, Wolfgang, and Gertrud Seiringer. “N-1-substituted Ethyl 4-Pyrazolecarboxylates: Synthesis and Spectroscopic Investigations,” J. Heterocyclic Chemistry (1993), vol. 30, 865-872.
Menozzi et al. “Synthesis of 5-Substituted 1-Aryl-1H-pyrazole-4-acetonitriles, 4-methyl-1-phenyl-1H-pyrazole-3-carbonitriles and Pharmacologically active 1-aryl-1H-pyrazole-4-acetic acids,” J. Heterocyclic Chem(1993), vol. 30, 997-1002.
Holzer, Wolfgang and Eva Schmid. “NMR Spectroscopic Investigations with Ethyl 1-(hetero)aryl-5-hydroxy-1H-pyrazole-4-carboxylates,” J. Heterocyclic Chem (1995), vol. 32, 1341-1349.
CAPLUS Accession No. 1987:598164, abstract of Palazzino et al, “1,3-diarylpyrazolo [4,5-c]- and -[5,4-c]-quinoloin-4-ones,” Journal of Med. Chem. 1997. 30(10), pp. 1737-1742.
CAPLUS Accession No. 1989:477949, abstract of Bajnati, “Conversion or 5-acetyluracil into pyrazole derivatives . . . ,” Bulletin de la Societe Chim. de France. 1988. (3), pp. 540-547.
CAPLUS Accession No. 1998:424227 abstract of Okazaki, “Prep of N-[5-membered heteroaryl-carbonyl]guanidine derivatives as Na+/H+ exchange inhibitors,” WO 9827061. Jun. 25, 1998.
J.E. Schultz et al.,Naunyn-Schmiedeberg's Arch Pharmacol., 333, pp. 23-30 (1986).
Z. Ma et al.,Tetrahedron: Asymmetry, vol. 8, No. 6, pp. 883-887 (1997).
A. Robichaud et al.,Neuropharmacology, 38, pp. 289-297 (1999).
R.A. Allen et al.,Biochemical Pharmacology, vol. 57, pp. 1375-1382 (1999).
J. Beavo et al., “Cyclic nucleotide phosphodiesterases: Structure, regulation and drug action,” Wiley and Sons, Chichester, pp. 3-14 (1990).
T.J. Torphy et al.,Drug News and Perspectives, 6, pp. 203-214 (1993).
M.A. Giembycz et al.,Clin. Exp. Allergy, 22, pp. 337-344 (1992).
J. Semmler et al.,Int. J. Immunopharmacol., 15, pp. 409-413 (1993).
K.L. Molnar-Kimber et al.,Mediators of Inflammation, 1, pp. 411-417 (1992).
M.W. Verghese et al.,J. Mol. Cell. Cardiiol., 21(Suppl. 2), S61 (1989).
C.P. Nielson et al.,J. Allergy Immunol., 86, pp. 801-808 (1990).
P.T. Peachell et al.,J. Immunol., 148, pp. 2503-2510 (1992).
G. Dent et al.,J. Pharmacol., 103, pp. 1339-1346 (1991).
S.A. Robicsek et al.,Biochem. Pharmacol., 42, pp. 869-877 (1991).
H.S. Dhillon et al.,J. Neurotrauma, 12, pp. 1035-1043 (1995).
N. Suttorp et al.,J. Clin. Invest., 91, pp. 1421-1428 (1993).
M.R. Bristow et al.,Circulation, 97, pp. 1340-1341 (1998).
G. Poli et al.,Proc. Natl. Acad. Sci. USA, 87, pp. 782-785 (1990).
P. Orosz et al.,J. Exp. Med., 177, pp. 1391-1398 (1993).
M. Mentz et al.,Blood, 88, pp. 2172-2182 (1996).
S. Takeda et al.,Kidney Int., 37, p. 362 (1990).
D. Chabardea et al.,Kidney Int., 35, p. 494 (1989).
C.D. Nicholson,Psychopharmacology, 101, p. 147 (1990).
F. Eckmann et al.,Curr. Ther. Res., 43, p. 291 (1988).
A. Klodzinska et al.,Neuropharmacology, 38, p. 1831 (1991).
H. Kato et al.,Eur. J. Pharmacol., 272, p. 107 (1995).
G. Gardos et al.,J. Clin. Pharmacol., 16, p. 304 (1976).
I. Shoulson et al.,Neurology, 25, p. 722 (1975).
T. Hayakawa et al.,Clin. Exp. Pharmacol. Physiol., 26, p. 421 (1999).
R.D. Porsolt et al.,Eur. J. Pharmacol., 47, p. 379 (1978).
R.D. Porsolt et al.,Eur. J. Pharmacol., 57, p. 431 (1979).
L. Steru,Psychopharmacology, 85, p. 376 (1985).
M. Takahashi,J. Neuroscience, 19, p. 610 (1999).
D. Pinsky et al.,J. Clin. Invest., 92, pp. 2994-3002 (1993).
Antidepressants: neurochemical, behavioral and clinical prospectives, Enna, Malick, and Richelson, eds., Raven Press, pp. 121-139 (1981).

Affiliated with

Also associated with

Rating

Cyclic AMP-specific phosphodiesterase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic AMP-specific phosphodiesterase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic AMP-specific phosphodiesterase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3680264